# Bristol Myers Squibb

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/bristol-myers-squibb
Canonical HTML page: https://getyourbrief.com/entity/bristol-myers-squibb

## Timeline

- **2026-03-21**: Litigation Filed — Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
- **2026-03-09**: DCAT Week 2026 — LOTTE Biologics engages in high-level partnership talks in New York City.
- **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance.
- **2026**: Cibotercept Data — Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
- **2025-12-01**: ADC Expansion — Completion of specialized ADC manufacturing lines at the Syracuse facility.
- **2025-Q3**: KER-050 Expansion — Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
- **2025-Q1**: Capital Infusion — Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
- **2024-03-15**: Songdo Groundbreaking — Construction begins on the first Mega Plant in Songdo, South Korea.
- **2023-01-01**: Syracuse Acquisition — LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
- **2022-04-18**: Partnership Termination — BMS and Nektar officially end their global clinical development collaboration.
- **2022-03-14**: Phase 3 Failure — Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
- **2018-02-14**: BMS Partnership — Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.

## Recent coverage (20 stories, network-wide)

### Oncologists Worldwide Cut Opdivo Doses by up to 92%, Defying FDA's 1-Year Rule
2026-08-20 09:12:50 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
Full story: https://gethealthbrief.com/story/fda-cancer-drug-dosing-challenge-health-systems

### Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate
2026-08-20 09:12:41 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Full story: https://getbiobrief.com/story/biotech-cancer-drug-dosing-challenge-keytruda-opdivo

### £300bn AstraZeneca-BMS Merger Faces Antitrust Firestorm Under Trump
2026-08-03 09:57:14 · Sector: legal · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The proposed mega-merger would immediately trigger intense antitrust reviews in the US, EU, and UK, testing the limits of Trump-era competition enforcement in the pharmaceutical sector. Significant divestitures and political pushback are likely, with a real risk of deal collapse.
Full story: https://getlegalbrief.com/story/astrazeneca-bms-merger-antitrust-300bn

### AstraZeneca-BMS £300bn Merger Could Reshape Global Drug Access and Pricing
2026-08-03 09:57:07 · Sector: health · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-healthcare-impact

### AZN Shares Crash 6.1% as £300bn Merger Talks Spook Investors
2026-08-03 09:57:00 · Sector: finance · Sentiment: Neutral · Impact: 9/10 · Sources: 4

AstraZeneca shares plummeted in London trading after reports of merger talks with Bristol Myers Squibb, as the market priced in execution risk, regulatory peril, and potential overpayment for a deal that would create a £300bn giant.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-merger-stock-market-impact

### AstraZeneca and BMS in Talks for £300bn Biotech Consolidation Play
2026-08-03 09:56:53 · Sector: bio · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Full story: https://getbiobrief.com/story/astrazeneca-bms-biotech-merger-300bn

### AZN-BMS $400B Talks: What It Means for Drug Prices and Access
2026-08-02 23:37:50 · Sector: health · Sentiment: Neutral · Impact: 9/10 · Sources: 2

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access

### AstraZeneca, BMS $400B Merger Talk Sparks Pharma M&A Frenzy
2026-08-02 23:37:40 · Sector: finance · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-400b-merger-talks-markets

### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
2026-08-02 23:37:29 · Sector: bio · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### 2 Dirt-Cheap Dividend Stocks Yielding 6.5% and 5.8%: PFE and BMY for $1,000
2026-07-08 21:25:08 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
Full story: https://getfinancebrief.com/story/dirt-cheap-dividend-stocks-pfe-bmy-finance

### Pfizer & Bristol Myers: 2 Dirt-Cheap Pharma Stocks Yielding 6%+ for Healthcare Investors
2026-07-08 21:22:01 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Full story: https://gethealthbrief.com/story/dirt-cheap-dividend-stocks-pfizer-bristol-myers-healthcare

### From Garage to S&P 500: Marvell’s $1 Trillion AI Bet Signals Startup Gold Rush
2026-06-15 01:27:56 · Sector: startups · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Marvell Technology’s S&P 500 inclusion highlights a $1 trillion AI infrastructure opportunity, signaling massive exit potential for deep tech startups in semiconductors and AI. Flex’s addition reflects manufacturing tech’s maturation. This index shakeup underscores sectors where venture capital is chasing the next big hidden gem.
Full story: https://getstartupbrief.com/story/marvell-trillion-ai-sp500-startups

### Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures
2026-03-22 02:52:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Full story: https://getbiobrief.com/story/nektar-therapeutics-class-action-litigation-pomerantz

### Nyxoah and Alumis Miss Q4 Earnings Estimates Amid Scaling R&D Costs
2026-03-20 01:55:28 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches.
Full story: https://getbiobrief.com/story/nyxoah-alumis-earnings-miss-q4-2026

### Nyxoah and Alumis Report Q4 Earnings Misses Amid Clinical Scaling Pressures
2026-03-20 01:55:23 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Full story: https://gethealthbrief.com/story/nyxoah-alumis-q4-earnings-miss-analysis

### New Cardiovascular Risks Identified in Patients with MCI and Dementia
2026-03-18 16:55:55 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
Full story: https://getbiobrief.com/story/cardiovascular-risks-mci-dementia-anticoagulants

### Cognitive Decline Linked to Increased Need for Anticoagulant Therapy
2026-03-18 16:52:26 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

New research indicates that patients with Mild Cognitive Impairment (MCI) and dementia are at a significantly higher risk for developing cardiovascular conditions requiring anticoagulants. This finding underscores the clinical challenge of managing stroke prevention in cognitively impaired populations with high fall risks.
Full story: https://gethealthbrief.com/story/cognitive-decline-anticoagulant-risk

### LOTTE Biologics Targets Global CDMO Expansion at DCAT Week 2026
2026-03-09 07:40:26 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

LOTTE Biologics is set to engage with global pharmaceutical leaders at DCAT Week 2026 in New York, aiming to secure strategic partnerships and showcase its expanding CDMO capabilities. The move underscores the company's aggressive push to become a top-tier global contract manufacturer by leveraging its Syracuse and Songdo facilities.
Full story: https://getbiobrief.com/story/lotte-biologics-dcat-week-2026-global-partnerships

### LOTTE Biologics Targets Global Expansion at DCAT Week 2026
2026-03-09 07:39:53 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Full story: https://gethealthbrief.com/story/lotte-biologics-dcat-week-2026-global-partnerships

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.